We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name LIXIANA®▼) plus a P2Y12 inhibitor...